UCB and Amgen announce positive phase 2 results of CDP7851/AMG785 in patients with post menopausal osteoporosis (PMO)

28-Apr-2011 - Belgium

UCB  and Amgen announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody CDP7851/AMG785 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of Postmenopausal Osteoporosis (PMO).

This Phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at month 12 for CDP7851/AMG785 active arms versus the placebo arm. In addition, CDP7851/AMG785 compared positively with the two active comparators, teriparatide and alendronate. The overall incidence of adverse events was generally balanced between groups. Consistent with previous studies, injection site reactions were reported more frequently in those patients receiving CDP7851/AMG785.

"The CDP7851/AMG785 project with Amgen is one of the most exciting pipeline programs in UCB’s immunology disease portfolio. The favorable comparison with established therapies indicates the potential for a change of treatment paradigms with CDP7851/AMG785 in PMO", said Prof. Dr. med. Iris Loew-Friedrich, Chief Medical Officer of UCB and Executive Vice-President Global Projects and Development. "We will now begin the in depth analysis of the data to prepare for the phase 3 program. The results fuel our energy working towards providing a new treatment option for the millions of women living with PMO."

The 12-month Phase 2 study is a multi-center, international, randomized, placebo-controlled, parallel-group study designed to evaluate the effect of CDP7851/AMG785 compared to placebo in women with low BMD, and to characterize the safety and tolerability of CDP7851/AMG785. Approximately 400 postmenopausal women with low BMD (T-scores between -2.0 and -3.5) are enrolled in the study. Treatment arms included dosing at 70, 140 and 210 mg subcutaneously once a month, and 140 and 210 mg every three months, against matched placebo for all treatment groups.

Detailed results will be submitted for presentation at a future medical congress.

CDP7851/AMG785 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, CDP7851/AMG785 is designed to allow the body to add more bone to the skeleton. Amgen and UCB have collaborated for the development of CDP7851/AMG785 for the treatment of bone-related conditions, including PMO and fracture healing.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous